Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19)
Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19)
复制标题
DOI：
10.1016/j.mayocp.2020.03.024
复制
发表时间：
2020-06-01
影响因子：
8.9
通讯作者：
Ackerman, Michael J.
中科院分区：
文献类型：
--
作者：
Giudicessi, John R.;Noseworthy, Peter A.;Ackerman, Michael J.
随着新型冠状病毒病（COVID-19）全球大流行在地球仪肆虐，预防和治疗这种致命疾病的竞赛导致了？标签外？羟基氯喹和洛匹那韦/利托那韦等药物的再利用，这些药物有可能导致不必要的QT间期延长和药物引起的心脏性猝死的风险。世界上很大一部分人口？鉴于美国人口很快可以接受具有致室性心动过速潜力的COVID-19药物治疗或暴露后预防，本文件旨在帮助医疗保健专业人员降低药物诱导的室性心律失常风险，同时最大限度地降低人员接触COVID-19的风险，并节省有限的个人防护设备供应。
As the coronavirus disease 19 (COVID-19) global pandemic rages across the globe, the race to prevent and treat this deadly disease has led to the ?off -label ? repurposing of drugs such as hydroxy- chloroquine and lopinavir/ritonavir, which have the potential for unwanted QT -interval prolongation and a risk of drug -induced sudden cardiac death. With the possibility that a considerable proportion of the world ?s population soon could receive COVID-19 pharmacotherapies with torsadogenic potential for therapy or postexposure prophylaxis, this document serves to help health care professionals mitigate the risk of drug -induced ventricular arrhythmias while minimizing risk of COVID-19 exposure to personnel and conserving the limited supply of personal protective equipment.